Tag Archives: Study

Study of Spanish youth transitioning to adult care shows positive outcomes, but some face challenges

A study of young people living with HIV in Spain found that after transitioning to adult clinics, virological suppression and CD4 count improved in the following three years. The study led by Dr David Aguilera-Alonso of the Hospital General Universitario Gregorio Marañón is one of the largest published descriptive studies about transition from paediatric care.… Read More »

People with NNRTI resistance have poorer responses to dolutegravir, South African study finds

People with HIV who already have resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI) when they start first-line antiretroviral treatment containing the integrase inhibitor dolutegravir were less likely to achieve viral suppression, a large clinical trial in South Africa has reported. NNRTI resistance has not been shown to affect responses to dolutegravir-based treatment previously. The… Read More »

Over 80 percent of COVID-19 patients have vitamin D deficiency, study finds

Over 80 percent of 200 COVID-19 patients in a hospital in Spain have vitamin D deficiency, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Vitamin D is a hormone the kidneys produce that controls blood calcium concentration and impacts the immune system. Vitamin D deficiency has been… Read More »

Keto diet vs calorie deficit study

A calorie is a unit of energy your body uses to perform hundreds of tasks. These include voluntary movements like walking, running, and jumping, as well as involuntary ones like breathing, circulating blood throughout your system, and maintaining normal body temperature. Your body needs a certain number of calories just to keep those involuntary processes… Read More »

Pfizer’s Ibrance kisses early breast cancer hopes goodbye with second study failure

After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »